Dr David Brown has over 30 years’ experience in the pharmaceutical / biotechnology industry both in research and in senior executive roles. He served with 4 of the top 10 Pharma companies: Zeneca, Pfizer, GlaxoWellcome, and Hoffman La-Roche; and also as President and Chief Executive of Cellzome AG, a biotechnology company headquartered in Heidelberg Germany. Whilst at Pfizer he was named co-inventor on the patent for Viagra, a treatment for male impotence, and he led the team that developed Viagra through to proof of clinical efficacy in human clinical trials. The active ingredient sildenafil is also used to treat pulmonary hypertension under the trade name Revatio. He also had a pivotal role in the discovery of Relpax, a treatment for migraine. Together these drugs have sales > $30 billion. While at Roche in Switzerland, he was a Director of the company and had responsibility for productivity of over 2000 staff focused on drug discovery at all six of Roche's research sites in the USA, Europe and Asia. He also served on Clinical Development and Business Development senior committees.
Since 2005 Dr Brown has pursued a portfolio of roles dedicated to bringing new medical treatments to both the developed and developing world. He has been heavily involved with OneWorld Health, San Francisco, (now called PATH Drug Solutions) where his work, and that of the organization, is dedicated to bringing medicines to the poorest of the poor in the world. In particular he has been responsible for development of a global strategy to reduce child deaths from diarrheal diseases and other gastrointestinal disorders. This work has been funded by Bill Gates through his charitable trust, the Bill and Melinda Gates Foundation. He is also co-founder and Chairman of a charity (FMVSO) supporting a school and orphanage for destitute children in India. In the developed world, his work focuses mostly on finding solutions to the growing problem of antibiotic resistance.